Since I happened to be listening to the webcast when you posted this, I guess that means I should reply.
I'd agree that this isn't a deal that I would have expected. It makes total sense for WPI, but I don't really see what AMGN gets out of the deal (they certainly didn't need the cash contribution), except maybe someone to hold hands with as they jump off the cliff.
I was interested in the discussion around the TNF biologics. Do you have a guess as to why they would do a cancer deal excluding AMGN oncology drugs, but not include TNF drugs while excluding enbrel?
Any comments here may have previously been disseminated on Twitter @BioDueDiligence or at www.biotechduediligence.com
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.